Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Hoffmann, Peter [VerfasserIn]   i
 Krisam, Johannes [VerfasserIn]   i
 Stremmel, Wolfgang [VerfasserIn]   i
 Gauss, Annika [VerfasserIn]   i
Titel:Real-world outcomes of vedolizumab therapy in ulcerative colitis and Crohn’s disease at a tertiary referral center
Verf.angabe:Peter Hoffmann, Johannes Krisam, Wolfgang Stremmel, Annika Gauss
Jahr:2019
Umfang:12 S.
Fussnoten:November 2018 ; Gesehen am 31.07.2019
Titel Quelle:Enthalten in: Digestive diseases
Ort Quelle:Basel : Karger, 1983
Jahr Quelle:2019
Band/Heft Quelle:37(2019), 1, Seite 33-44
ISSN Quelle:1421-9875
Abstract:<b><i>Background:</i></b> Vedolizumab was approved for the therapy of ulcerative colitis and Crohn’s disease in mid-2014. Real-world treatment data are necessary for a balanced assessment of its position among other therapeutic options. <b><i>Summary:</i></b> Patients with ulcerative colitis or Crohn’s disease, initiating vedolizumab therapy at the outpatient clinic for inflammatory bowel diseases at the University Hospital ­Heidelberg between June 1, 2014 and August 31, 2016, were recruited based on electronic medical records. The primary study endpoint was response at week 30, while the secondary endpoints were the need for surgery and discontinuation of therapy due to inadequate response, or adverse events. Twenty-five patients with ulcerative colitis (40% anti-tumor necrosis factor α [TNFα] naive) and 28 patients with Crohn’s disease (10.7% anti-TNFα naive, 53.6% having undergone at least one intestinal surgery) were enrolled. Among the ulcerative colitis patients, 20% achieved remission, 32% partial response, and 48% were non-responders to vedolizumab. In Crohn’s disease, 14.3% of the patients achieved remission, 46.4% partial response, and 39.4% were non-responders. Two patients discontinued vedolizumab therapy due to suspected side effects. <b><i>Key Message:</i></b> In a relatively treatment-refractory cohort of inflammatory bowel disease patients, vedolizumab was efficacious in achieving response. However, the majority of the patients were not satisfactorily treated, as they did not reach remission.
DOI:doi:10.1159/000492322
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1159/000492322
 Volltext: https://www.karger.com/Article/FullText/492322
 DOI: https://doi.org/10.1159/000492322
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1670310264
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68414366   QR-Code
zum Seitenanfang